BioViva USA Inc. develops gene therapies utilizing adeno-associated virus (AAV) and cytomegalovirus (CMV) platforms to deliver larger genetic payloads for treating aging and age-related diseases. The company addresses the significant health challenges posed by chronic conditions linked to cellular aging, aiming to extend healthy human lifespans with fewer treatment interventions.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic diseases linked to cellular aging, such as heart disease, dementia, diabetes, and frailty, are major contributors to mortality. Addressing these complex disorders requires therapeutic strategies that can effectively target the underlying mechanisms of aging.
Solution
BioViva USA Inc. is developing gene therapies designed to address aging and age-related diseases. The company utilizes adeno-associated virus (AAV) and cytomegalovirus (CMV) platforms to deliver genetic payloads that promote more youthful cellular behavior. BioViva's CMV gene therapy platform supports larger genetic payloads, potentially minimizing the number of treatments required for patients with complex diseases. The company's therapeutics are designed to ward off the degeneration associated with aging.
Target Audience
The primary target audience includes individuals affected by aging-related diseases and those interested in gene therapy advancements, as well as universities, companies, and researchers in the gene therapy space.
Features
- AAV-based gene therapy platform for delivering genetic material.
- CMV-based gene therapy platform capable of carrying larger genetic payloads.
- Therapeutics designed to help patient cells behave more youthfully.
- Open-access database (CodeKeeper™) for gene therapy information.